- Home
- BPMC vs GKOS Comparison
BPMC vs GKOS Comparison
Compare BPMC & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPMC
- GKOS
- Stock Information
- Founded
- BPMC 2008
- GKOS 1998
- Country
- BPMC United States
- GKOS United States
- Employees
- BPMC N/A
- GKOS N/A
- Industry
- BPMC Biotechnology: Pharmaceutical Preparations
- GKOS Medical/Dental Instruments
- Sector
- BPMC Health Care
- GKOS Health Care
- Exchange
- BPMC Nasdaq
- GKOS Nasdaq
- Market Cap
- BPMC 5.9B
- GKOS 6.7B
- IPO Year
- BPMC 2015
- GKOS 2015
- Fundamental
- Price
- BPMC $86.43
- GKOS $129.41
- Analyst Decision
- BPMC Buy
- GKOS Strong Buy
- Analyst Count
- BPMC 17
- GKOS 12
- Target Price
- BPMC $120.18
- GKOS $130.75
- AVG Volume (30 Days)
- BPMC 496.2K
- GKOS 453.3K
- Earning Date
- BPMC 10-24-2024
- GKOS 10-30-2024
- Dividend Yield
- BPMC N/A
- GKOS N/A
- EPS Growth
- BPMC N/A
- GKOS N/A
- EPS
- BPMC N/A
- GKOS N/A
- Revenue
- BPMC $362,796,000.00
- GKOS $341,725,000.00
- Revenue This Year
- BPMC $102.50
- GKOS $21.15
- Revenue Next Year
- BPMC $37.31
- GKOS $23.98
- P/E Ratio
- BPMC N/A
- GKOS N/A
- Revenue Growth
- BPMC 60.80
- GKOS 15.14
- 52 Week Low
- BPMC $43.89
- GKOS $59.22
- 52 Week High
- BPMC $121.90
- GKOS $136.61
- Technical
- Relative Strength Index (RSI)
- BPMC 30.17
- GKOS 54.58
- Support Level
- BPMC $92.23
- GKOS $131.74
- Resistance Level
- BPMC $96.50
- GKOS $136.61
- Average True Range (ATR)
- BPMC 2.79
- GKOS 3.49
- MACD
- BPMC 0.02
- GKOS -0.44
- Stochastic Oscillator
- BPMC 16.01
- GKOS 44.78
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.